References
- Hirte H, Poon R, Yao X, et al. Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Crit Rev Oncol Hematol. 2021;162:103324. doi: 10.1016/j.critrevonc.2021.103324
- Alves RC, Fernandes RP, Eloy JO, et al. Characteristics, properties and analytical methods of paclitaxel: a review. Crit Rev Anal Chem. 2018;48(2):110–118. doi: 10.1080/10408347.2017.1416283
- Sendo T, Sakai N, Itoh Y, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol. 2005;56(1):91–96. doi: 10.1007/s00280-004-0924-9
- Yanaranop M, Chaithongwongwatthana S. Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: a double-blind randomized controlled trial. Asia Pac J Clin Oncol. 2016;12(3):289–299. doi: 10.1111/ajco.12495
- Dubinsky S, Patel D, Wang X, et al. Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis. Support Care Cancer. 2022;30(7):5627–5644. doi: 10.1007/s00520-022-06891-0
- Noetzlin S, Breville G, Seebach JD, et al. Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach. Swiss Med Wkly. 2022;152(102):w30088. doi: 10.4414/SMW.2022.w30088
- Mayayo-Peralta I, Zwart W, Prekovic S. Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene? Endocr Relat Cancer. 2021;28(6):R157–R171. doi: 10.1530/ERC-20-0489
- Bakour N, Moriarty F, Moore G, et al. Prognostic significance of glucocorticoid receptor expression in cancer: a systematic review and meta-analysis. Cancers (Basel). 2021;13(7):1649. doi: 10.3390/cancers13071649
- Melhem A, Yamada SD, Fleming GF, et al. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009;15(9):3196–3204. doi: 10.1158/1078-0432.CCR-08-2131
- Yin L, Fang F, Song X, et al. The pro-adhesive and pro-survival effects of glucocorticoid in human ovarian cancer cells. J Mol Endocrinol. 2016;57(1):61–72. doi: 10.1530/JME-15-0142
- Karvonen H, Arjama M, Kaleva L, et al. Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. Cell Death Dis. 2020;11(9):790. doi: 10.1038/s41419-020-03009-4
- Munster PN, Greenstein AE, Fleming GF, et al. Overcoming taxane resistance: preclinical and phase 1 studies of relacorilant, a selective glucocorticoid receptor modulator, with nab-paclitaxel in solid tumors. Clin Cancer Res. 2022;28(15):3214–3224. doi: 10.1158/1078-0432.CCR-21-4363
- Lansinger OM, Biedermann S, He Z, et al. Do steroids matter? A retrospective review of premedication for taxane chemotherapy and hypersensitivity reactions. J Clin Oncol. 2021;39(32):3583–3590. doi: 10.1200/JCO.21.01200
- Berek JS, Kehoe ST, Kumar L, et al. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obst. 2018;143(S2):59–78. doi: 10.1002/ijgo.12614
- Amant F, Mirza MR, Koskas M, et al. Cancer of the corpus uteri. Int J Gynecol Obst. 2018;143(S2):37–50. doi: 10.1002/ijgo.12612
- Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri. Int J Gynecol Obst. 2018;143(S2):22–36. doi: 10.1002/ijgo.12611
- Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049–1060. doi: 10.2307/2531734
- Picard M, Castells MC. Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. Clin Rev Allerg Immunol. 2015;49(2):177–191. doi: 10.1007/s12016-014-8416-0
- Markman M, Kennedy A, Webster K, et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18(1):102–105. doi: 10.1200/JCO.2000.18.1.102
- Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol. 2002;84(3):420–425. doi: 10.1006/gyno.2001.6546
- O’Cathail SM, Shaboodien R, Mahmoud S, et al. Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies. Int J Gynecol Cancer. 2013;23(7):1318–1325. doi: 10.1097/IGC.0b013e31829f1799
- Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 2002;41(5):418–424. doi: 10.1080/028418602320404998
- Köppler H, Heymanns J, Weide R. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie. 2001;24(3):283–285. doi: 10.1159/000055093
- Bookman MA, Kloth DD, Kover PE, et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol. 1997;8(6):611–614. doi: 10.1023/A:1008207025430
- Chen FC, Wang LH, Zheng XY, et al. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions. Oncotarget. 2017;8(12):19236–19243. doi: 10.18632/oncotarget.13705
- Cox JM, van Doorn L, Malmberg R, et al. The added value of H2 antagonists in premedication regimens during paclitaxel treatment. Br J Cancer. 2021;124(10):1647–1652. doi: 10.1038/s41416-021-01313-0
- Foreman E, Polwart C, Walker A, et al. Histamine-2 (H 2) antagonists can be safely removed from standard paclitaxel premedication regimens. Brit J Clin Pharma. 2022;88(9):4191–4198. doi: 10.1111/bcp.15363
- Haine AI, Notenboom C, Tan LVP, et al. Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study. Pharmacol Res Perspect. 2022;10(4):e00985. doi: 10.1002/prp2.985
- Huntjens DW, Vanhommerig JW, van de Veen W, et al. Exclusion of ranitidine from premedication regimens during paclitaxel treatment. JAMA Oncol. 2023;10(1):131. doi: 10.1001/jamaoncol.2023.4821
- Montero Pérez O, Martinez Benavides J, González Fernandez T, et al. Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study. Expert Rev Clin Pharmacol. 2023;16(9):877–883. doi: 10.1080/17512433.2023.2238596
- Chen W, Mempel M, Schober W, et al. Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy. 2008;63(11):1418–1427. doi: 10.1111/j.1398-9995.2008.01880.x
- De Martinis M, Sirufo MM, Suppa M, et al. Sex and gender aspects for patient stratification in allergy prevention and treatment. Int J Mol Sci. 2020;21(4):1535. doi: 10.3390/ijms21041535
- Goromaru T, Itoh Y, Sendo T, et al. Ovariectomy aggravates hypersensitivity reactions to paclitaxel in rats. Cancer Biol Ther. 2005;4(2):225–230. doi: 10.4161/cbt.4.2.1475